Polymorphism of biotransformation genes and risk of relapse in childhood acute leukemia

Balkan Journal of Medical Genetics

Volumn 12, Issue 1, 2009, Pages 21-35

  Gra, O A ^a,b   Kozhekbaeva, Z H M ^a,b,c   Makarova, O V ^d   Samochatova, E V ^d   Nasedkina, T V ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b VAVILOV INSTITUTE OF GENERAL GENETICS   (Russian Federation)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Childhood acute leukemia; Microarray; Polymorphism; Predisposition; Relapse

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARYLAMINE ACETYLTRANSFERASE; ASPARAGINASE; CYTARABINE; CYTOCHROME P450 1A1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DAUNORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; MERCAPTOPURINE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BIOCHIP; BIOTRANSFORMATION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RELAPSE;

EID: 70350752452     PISSN: 13110160     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10034-009-0008-6     Document Type: Article

References (45)

1. Wood ME, Philips GK. Hematology/Oncology Secrets. 3rd ed. Philadelphia: Hanley & Belfus Inc., 2003.
2. Chan KW. Acute lymphoblastic leukemia. Curr Probl Pediatr Adolesc Health Care 2002; 32(2): 40-49.
3. Ansari M, Krajinovic M. Pharmacogenomics of acute leukemia. Pharmacogenomics 2007; 8(7): 817-834.
4. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998; 91(5): 1716-1722. (Pubitemid 28110337)
5. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12(3): 346-352.
6. Chupova NV, Samochatova EV, Rudneva AE, Solopova GG, Nasedkina TV, Fedorova OE, Glotov AS, Zemliakova VV, Krynetski EYu, Krynetskaia NF, Ribeiro RC, Evans WE, Rumyantsev AG. Genetic polymorphism of thiopurine-S- methyltransferase and treatment of childhood acute lymphoblastic leukemia. Haematol Transfusiol (in Russian with English abstract) 2005; 6: 3-8.
7. Gra OA, Glotov AS, Nikitin EA, Glotov OS, Kuznetsova VE, Chudinov AV, Sudarikov AB, Nasedkina TV. Polymorphisms in xenobiotic-metabolizing genes and the risk of chronic lymphocytic leukemia and non-Hodgkin's lymphoma in adult Russian patients. Am J Hematol 2008; 83(4): 279-287.
8. Gra OA, Glotov AS, Kozhekbaeva ZhM, Makarova OV, Nasedkina TV. Genetic polymorphism of GST, NAT2, and MTRR and susceptibility to childhood acute leukemia. Mol Biol (Mosk) 2008; 42(2): 187-197.
9. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004; 96(2): 134-144. (Pubitemid 38195904)
10. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig WD, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293(12): 1485-1489.
11. Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2000; 9(6): 557-562.
12. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 1999; 93(5): 1496-1501.
13. Smith MT, Wang Y, Skibola CF, Slater DJ, Lo Nigro L, Nowell PC, Lange BJ, Felix CA. Low NAD(P)H: quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 2002; 100(13): 4590-4593.
14. Infante-Rivard C, Labuda D, Krajinovic M, Sinnett D. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology 1999; 10(5): 481-487.
15. Takanashi M, Morimoto A, Yagi T, Kuriyama K, Kano G, Imamura T, Hibi S, Todo S, Imashuku S. Impact of glutathione S-transferase gene deletion on early relapse in childhood B-precursor acute lymphoblastic leukemia. Haematologica 2003; 88(11): 1238-1244.
16. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, Sinnett D. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002; 8(3): 802-810.
17. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105(12): 4752-4758. (Pubitemid 40807300)
18. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000; 95(4): 1222-1228.
19. Voso MT, D'Alo F, Gumiero D, Guidi F, Hohaus S, Leone G. The CYP1A1*2a allele is an independent prognostic factor for acute myeloid leukemia. Haematologica 2005; 90(7): 982-984.
20. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K, Stanulla M. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Pharmacogenetics 2000; 10(8): 715-726.
21. Glotov AS, Nasedkina TV, Ivashchenko TE, Iurasov RA, Surzhikov SA, Pan'kov SV, Chudinov AV, Baranov VS, Zasedatelev AS. Biochip development for polymorphism analysis in biotransformation system genes. Mol Biol (Mosk) 2005; 39(3): 403-412.
22. Nasedkina TV, Fedorova OE, Glotov AS, Chupova NV, Samochatova EV, Maiorova OA, Zemlyakova VV, Roudneva AE, Chudinov AV, Yurasov RA, Kozhekbaeva JM, Barsky VE, Krynetskiy EY, Krynetskaia NF, Cheng C, Ribeiro RC, Evans WE, Roumyantsev AG, Zasedatelev AS. Rapid genotyping of common deficient thiopurine Smethyltransferase alleles using the DNA-microchip technique. Eur J Hum Genet 2006; 14(9): 991-998.
23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Warrenton,VA, USA, November 1997. Hematol J 2000; 1(1): 53-66.
24. Surzhikov SA, Timofeev EN, Chernov BK, Golova JB, Mirzabekov AD. Advanced method for oligonucleotide deprotection. Nucleic Acids Res 2000; 28(8):E29.
25. Rubina AY, Pan'kov SV, Dementieva EI, Pen'kov DN, Butygin AV, Vasiliskov VA, Chudinov AV, Mikheikin AL, Mikhailovich VM, Mirzabekov AD. Hydrogel drop microchips with immobilized DNA: properties and methods for large-scale production. Anal Biochem 2004; 325(1): 92-106.
26. Celander M, Weisbrod R, Stegeman JJ. Glu- cocorticoid potentiation of cytochrome P4501A1 induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin in porcine and human endothelial cells in culture. Biochem Biophys Res Commun 1997; 232(3): 749-753.
27. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54(16): 4313-4320.
28. Yuan ZM, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 1991; 19(3): 625-629.
29. Vester U, Kranz B, Zimmermann S, Buscher R, Hoyer PF. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases- M1 and -P1. Pediatr Nephrol 2005; 20(4): 478-481.
30. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005; 37(4): 611-703.
31. Papageorgiou G, Iliadis S, Botsoglou N, Dioudis C, Goulas A, Fletouris D, Dimitriadou-Vafiadou A. Lipid peroxidation of rat myocardial tissue following daunomycin administration. Toxicology 1998; 126(2): 83-91.
32. Autrup JL, Hokland P, Pedersen L, Autrup H. Effect of glutathione S-transferases on the survival of patients with acute myeloid leukaemia. Eur J Pharmacol 2002; 438(1-2): 15-18.
33. Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 2002; 3(1): 19-30.
34. Goldenkova-Pavlova IV, Bruskin SA, Abdeev RM, Markarova EV, Bigvava SG, Radkevich LA, Kozhekbaeva ZhM, Glotov AS, Gra OA, Zasedatelev AS, Nasedkina TV, Kurdanov KhA, Piruzian ES. Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping. Genetika 2006; 42(8): 1143-1150.
35. Kozhekbaeva ZhM, Glotov AS, Gra OA, Golden-kova-Pavlova IV, Bruskin SA, Agafonova EE, Markarova EV, Abdeev RM, Korsunskaia IM, Piruzian AL, Barskii VE, Zasedatelev AS, Nasedkin TV. Identification of functionally significant mutations in NAT2 gene using biological microchips. Mol Biol (Mosk) 2007; 41(4): 725-733.
36. Leff MA, Fretland AJ, Doll MA, Hein DW. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 1999; 274(49): 34519-34522.
37. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25(11): 1649-1658.
38. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet 2006; 7: 58.
39. Chiou HL, Wu MF, Chien WP, Cheng YW, Wong RH, Chen CY, Lin TS, Lee H. NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan. Cancer Lett 2005; 223(1): 93-101.
40. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-296.
41. Acar H, Caliskan U, Demirel S, Largaespada DA. Micronucleus incidence and their chromosomal origin related to therapy in acute lymphoblastic leukemia (ALL) patients: detection by micronucleus and FISH techniques. Teratog Carcinog Mutagen 2001; 21(5): 341-347.
42. Emoto Y, Kisaki H, Manome Y, Kharbanda S, Kufe D. Activation of protein kinase Cä in human myeloid leukemia cells treated with 1-â- Darabinofuranosylcytosine. Blood 1996; 87(5): 1990-1996.
43. Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995; 89(2): 364-372.
44. Schroeder H, Garwicz S, Kristinsson J, Siimes MA, Wesenberg F, Gustafsson G. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol 1995; 25(5): 372-378.
45. Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, Broadfield ZJ, Harris RL, Taylor KE, Gibson BE, Hann IM, Hill FG, Kinsey SE, Eden TO, Mitchell CD, Harrison CJ. Outcome heterogeneity in childhood highhyperdiploid acute lymphoblastic leukemia. Blood 2003; 102(8): 2756-2762. (Pubitemid 37248844)